The emergence of biosimilar insulin preparations-A cause for concern?

Diabetes Technology and Therapeutics

Volumn 14, Issue 11, 2012, Pages 989-996

  Owens, David R ^a   Landgraf, Wolfgang ^b,c   Schmidt, Andrea ^b   Bretzel, Reinhard G ^d   Kuhlmann, Martin K ^e  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASALOG; BIOSIMILAR AGENT; BIOSULIN; BONGLIXAN; GENSULIN; GLARITUS; INSUGEN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; NEUTRAL INSULIN; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG; WOSULIN;

ANAPHYLAXIS; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURIFICATION; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; FEMALE; HUMANS; INSULIN; MALE; THERAPEUTIC EQUIVALENCY;

EID: 84868017986     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0105     Document Type: Review

References (45)

1. Covic A, Kuhlmann M: Biosimilars: recent developments. Int Urol Nephrol 2007;39:261-266. (Pubitemid 46722974)
2. Dranitsaris G, Amir E, Dorward K: Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 2011;71:1527-1536.
3. Krämer I, Sauer T: The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis 2010;10:163-171.
4. Casadevall N, Nataf J, Viron B Kolta A, Kiladjian JJ, Martin- Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475. (Pubitemid 34441737)
5. Schellekens H, Jiskoot W: Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol 2006;24:613-614. (Pubitemid 43884419)
6. U.S. Food and Drug Administration: Facts about generic drugs. U.S. Department of Health and Human Services. 2012. www.fda.gov/Drugs/ ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ ucm167991.htm (accessed August 2012).
7. Committee for Medicinal Products for Human Use: Guideline on similar biological medicinal products. CHMP/437/04 2005. 2005. www.ema.europa.eu/docs/ en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf (accessed August 2012).
8. Committee for Products for Human Use: Guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/42832/2005. 2005. www.ema.europa .eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003920.pdf (accessed August 2012).
9. World Health Organization: Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Press. 2009. www.who.int/biologicals/areas/ biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf (accessed August 2012).
10. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, Vleminckx C, Wadhwa M, Schneider CK: Biosimilars - why terminology matters. Nat Biotechnol 2011;29:690-693.
11. Heinemann L, Hompesch M: Biosimilar insulins: how similar is similar? J Diabetes Sci Technol 2011;5:741-754.
12. Kuhlmann M, Marre M: Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 2010;10:90-97.
13. Schellekens H: Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-462. (Pubitemid 37361488)
14. Schellekens H: The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol 2008;3:174-178.
15. Kessler M, Goldsmith D, Schellekens H: Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21:v9-v12. (Pubitemid 44391026)
16. Yanai H, Adachi H, Hamasaki H: Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine. Diabetes Care 2011;34:e108.
17. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS: Immunological responses to exogenous insulin. Endocr Rev 2007;28:625-652. (Pubitemid 47606649)
18. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W: Structure- immunogenicity relationships of therapeutic proteins. Pharm Res 2004;21:897-903. (Pubitemid 38870136)
19. Rosenberg A: Effects of protein aggregates: an immunologic perspective. AAPS J 2006;8:E501-E507. (Pubitemid 44294011)
20. Ladisch MR, Kohlmann KL: Recombinant human insulin. Biotechnol Prog 1992;8:469-478.
21. EDQM: Insulin glargine [draft monograph]. Pharmeuropa Online 2011;23:327-328. www.edqm.eu/store/images/majbdd/201103071151570. Contents%20of%20Phpa2302E.pdf (accessed August 2012).
22. Schmidt A, Schaefer E, Schmeier E, Jochum M: By-product profile of insulin glargine preparations: a fingerprint of the biotechnological production process [abstract P-1429]. Presented at the World Diabetes Congress of the International Diabetes Federation, Dubai, 2011.
23. Kannan V, Narayanaswamy P, Gadamsetty D, Hazra P, Khedkar A, Iyer H: A tandem mass spectrometric approach to the identification of O-glycosylated glargine glycoforms in active pharmaceutical ingredient expressed in Pichia pastoris. Rapid Commun Mass Spectrom 2009;23:1035-1042.
24. Li J, Liang C, Zhang H, Yang H, Wang D: Structu al identification and qualitative analysis of recombinant insulin glargine-related impurities [in Chinese; English abstract]. Chin Pharm J 2008;43:1-12.
25. Committee for Medicinal Products for Human Use: Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues. Guidance on similar medicinal products containing recombinant human insulin. EMEA/CHMP/32775/2005. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500003957.pdf (accessed August 2012).
26. Committee for Medicinal Products for Human Use: Guideline on immunogenicity assessment of biotechnologyderived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006. www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003947.pdf (accessed August 2012).
27. Committee for Medicinal Products for Human Use: Concept paper on the revision of the guideline on nonclinical and clinical development of similar biological medicinal products containing recombinant human insulin. EMA/CHMP/ BMWP/506470/2011. www.ema.europa.eu/ema/doc-index .jsp?curl = pages/includes/document/document-detail.jsp? webContentId =WC500109587&murl = menus/document- library/document-library.jsp&mid = 0b01ac058009a3dc (accessed August 2012).
28. Johnson IS: Human insulin from recombinant DNA technology. Science 1983;219:632-637. (Pubitemid 13185414)
29. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ: Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003;63:1743-1778. (Pubitemid 36999964)
30. Cheng SW, Lu JM, Pan CU, Wang BA, Wang YZ, Li YJ, Yang G, Zuo WH: Studies of pharmacokinetic, pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man [in Chinese]. Chin J Diabetes 2010;18:387-393.
31. Zhu L, He L, Gu Q, Zhang Y, Zou D: A study on the control of fasting and postprandial hyperglycemia by glargine insulin combined with oral hypoglycemic agent [in Chinese]. Chin J Diabetes 2009;17:690-692.
32. Verma M, Hazra P, Iyer H, Arun A, Akundi S, Dixit M, Eswaraiah A, Prasanna C, Atigna A: Basalog is similar to Lantus in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Countries 2011;31:26-31.
33. Instituto Nacionalde Vigilanciade Medicamentosy Alimentos: Sala especializada de medicamentos y productos bioló gicos de la comisio'n revisora, Acta No. 31. Ministerio de la Proteccio'n Social, Bogata, Repú blicade Colombia. 2009. http://web.invima.gov.co/portal/documents/portal/ documents/root/acta312009-medicamentos.pdf (accessed August 2012).
34. Gan&Lee News: Gan&Lee and LG officially signed sales agreements on overseas markets. 2006. www.ganlee.com/en/?optionid = 422&auto-id = 10 (accessed August 2012).
35. European Medicines Agency: Pre-authorisation evaluation of medicines for human use: withdrawal assessment report for insulin human 30/70 Mix Marvel. EMEA/CHMP/70179/2008. www.ema.europa.eu/docs/en-GB/document-library/Application- withdrawal-assessment-report/2010/01/WC500067169.pdf (accessed August 2012).
36. European Medicines Agency: Pre-authorisation evaluation of medicines for human use: withdrawal assessment report for insulin human Long Marvel. EMEA/CHMP/70349/2008. www.ema.europa.eu/docs/en-GB/document-library/Application- withdrawal-assessment-report/2010/01/WC500067170pdf (accessed August 2012).
37. European Medicines Agency: Pre-authorisation evaluation of medicines for human use: withdrawal assessment report for insulin human Rapid Marvel. EMEA/CHMP/317778/ 2007. www.ema.europa.eu/docs/en-GB/document-library/ Application-withdrawal-assessment-report/2010/01/ WC500067086.pdf (accessed August 2012).
38. European Medicines Agency Press Release: Marvel Life- ciences Ltd withdraws its marketing authorisation applications for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel. EMEA/2435/2008. www.ema.europa.eu/docs/en-GB/document-library/Press-release/ 2009/11/WC500015335.pdf (accessed August 2012).
39. Johnson JA: FDA regulation of follow-on biologics. RL34045. 2010. www.primaryimmune.org/advocacy-center/pdfs/health-care-reform/ Biosimilars-Congressional-Research-Service-Report.pdf (accessed August 2012).
40. U.S. Senate: Improving access to innovative medical therapies: Biologics Price Competition and Innovation Act of 2009. U.S. Department of Health and Human Services. 2010. www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/UCM216146.pdf (accessed August 2012).
41. Niederwieser D, Schmitz S: Biosimilar agents in oncology/haemotology: from approval to practice. Eur J Haematol 2011;4:277-288.
42. Kozlowski S, Woodcock J, Midthun K, Sherman RB: Developing the nation's biosimilars program. N Engl J Med 2011; 365:385-388.
43. Mounho B, Phillips A, Holcombe K, Grampp G, Lubiniecki T, Mollerup I, Jones C: Global regulatory standards for the approval of biosimilars. Food Drug Law J 2010;65:819-837.
44. Joshi SR: Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India 2011;59(Suppl):44-47.
45. Shrivastava B: No drug side effects, reports India. OneWorld South Asia. 2008. http://southasia.oneworld.net/today sheadlines/no-drug-side-effects- reports-india/?searchterm = adverse drug reactions (accesssed August 2012).